Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

Home October 15, 2021
Home
News | Cardiovascular Business

October 15, 2021 — The American Heart Association (AHA) released a new policy statement that offers policy ...

Home October 15, 2021
Home
News | Stents Carotid

October 15, 2021 — The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery ...

Home October 15, 2021
Home
Videos | Structural Heart

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...

Home October 14, 2021
Home
News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.
Feature | BY Dave Fornell, DAIC Editor

October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home October 06, 2021
Home
A comparison between healthy artery (left) and inflamed artery (right) using perivascular fat attenuation index (FAI) mapping to detect spatial changes in perivascular fat composition induced by inflammation of the vascular wall caused by high-risk plaques.
Feature | Computed Tomography (CT)

October 6, 2021 — Data presented during the late-breaking science session at the European Society of Cardiology (ESC) 20 ...

Home October 06, 2021
Home
News | Structural Heart Occluders

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

October 4, 2021 —  One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...

Home October 04, 2021
Home
Videos | Structural Heart

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

Home September 28, 2021
Home
Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being  deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.
Feature | Left Atrial Appendage (LAA) Occluders

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

Home September 27, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

Home September 20, 2021
Home
The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
Subscribe Now